Hepion Pharmaceuticals, Inc. SEC filings CTRVP
Hepion Pharmaceuticals, Inc. has 723 filings in SEC EDGAR's recent list, going back to Aug 8, 2013. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 9, 2026 (material agreement, acquisition or sale of assets, unregistered share sale, officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14C | Information statement | Sep 10, 2026 | Sep 10, 2026 |
| PRE 14C | Filing | Aug 31, 2026 | Aug 28, 2026 |
| DEFA14A | Additional proxy material | Apr 28, 2026 | — |
| DEF 14A | Proxy statement | Apr 28, 2026 | Apr 28, 2026 |
| DEF 14A | Proxy statement | Apr 28, 2025 | Apr 28, 2025 |
| PRE 14A | Preliminary proxy statement | Apr 16, 2025 | Apr 16, 2025 |
| DEF 14A | Proxy statement | Feb 7, 2025 | Feb 7, 2025 |
| PRE 14A | Preliminary proxy statement | Jan 27, 2025 | Jan 27, 2025 |
| DEFA14A | Additional proxy material | Dec 5, 2024 | — |
| DEFA14A | Additional proxy material | Dec 2, 2024 | — |
| DEFA14A | Additional proxy material | Apr 28, 2023 | — |
| DEF 14A | Proxy statement | Apr 28, 2023 | Jun 22, 2023 |
| DEF 14A | Proxy statement | Nov 21, 2022 | Dec 15, 2022 |
| PRE 14A | Preliminary proxy statement | Nov 9, 2022 | Dec 15, 2022 |
| DEFA14A | Additional proxy material | Jul 26, 2022 | — |
| DEFA14A | Additional proxy material | Jul 25, 2022 | — |
| DEFA14A | Additional proxy material | Jun 30, 2022 | — |
| DEFA14A | Additional proxy material | Jun 24, 2022 | — |
| DEFA14A | Additional proxy material | Jun 14, 2022 | — |
| DEFA14A | Additional proxy material | May 31, 2022 | — |
| DEF 14A | Proxy statement | Apr 29, 2022 | Jun 24, 2022 |
| PRE 14A | Preliminary proxy statement | Apr 20, 2022 | Apr 20, 2022 |
| DEF 14A | Proxy statement | Sep 7, 2021 | Oct 7, 2021 |
| PRE 14A | Preliminary proxy statement | Aug 23, 2021 | Oct 3, 2021 |
| DEFA14A | Additional proxy material | Jun 25, 2021 | — |
| DEF 14A | Proxy statement | May 12, 2021 | Jun 25, 2021 |
| PRE 14A | Preliminary proxy statement | Apr 28, 2021 | Apr 28, 2021 |
| DEF 14A | Proxy statement | Jun 12, 2020 | Jul 30, 2020 |
| DEF 14A | Proxy statement | Apr 2, 2019 | May 2, 2019 |
| PRE 14A | Preliminary proxy statement | Mar 18, 2019 | Apr 19, 2019 |
| DEFA14A | Additional proxy material | Nov 30, 2018 | — |
| DEF 14A | Proxy statement | Nov 29, 2018 | Jan 15, 2019 |
| DEFA14A | Additional proxy material | Feb 21, 2018 | — |
| DEF 14A | Proxy statement | Jan 24, 2018 | Feb 21, 2018 |
| PRE 14A | Preliminary proxy statement | Jan 12, 2018 | Feb 21, 2018 |
| DEFA14A | Additional proxy material | Dec 13, 2017 | — |
| DEFA14A | Additional proxy material | Dec 6, 2017 | — |
| DEFA14A | Additional proxy material | Oct 27, 2017 | — |
| DEF 14A | Proxy statement | Oct 27, 2017 | Dec 13, 2017 |
| DEFA14A | Additional proxy material | Oct 31, 2016 | — |
| DEF 14A | Proxy statement | Oct 28, 2016 | Dec 14, 2016 |
| DEFA14A | Additional proxy material | Dec 15, 2015 | — |
| DEF 14A | Proxy statement | Dec 15, 2015 | Feb 4, 2016 |
| DEF 14A | Proxy statement | Oct 27, 2014 | Dec 2, 2014 |
| PRE 14A | Preliminary proxy statement | Oct 17, 2014 | Dec 1, 2014 |
Showing 45 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- HEPA (OTC), CTRVP (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Red Bank, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1583771
- Former names
- ContraVir Pharmaceuticals, Inc. (until Jul 23, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.